122 related articles for article (PubMed ID: 15451569)
1. Inhibins and ovarian cancer.
Robertson DM; Pruysers E; Burger HG; Jobling T; McNeilage J; Healy D
Mol Cell Endocrinol; 2004 Oct; 225(1-2):65-71. PubMed ID: 15451569
[TBL] [Abstract][Full Text] [Related]
2. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
[TBL] [Abstract][Full Text] [Related]
3. Inhibin as a diagnostic marker for ovarian cancer.
Robertson DM; Pruysers E; Jobling T
Cancer Lett; 2007 Apr; 249(1):14-7. PubMed ID: 17320281
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
5. [Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women].
Markova D; Milchev N; Batashki I; Uchikov A
Akush Ginekol (Sofiia); 2008; 47(1):16-9. PubMed ID: 18642569
[TBL] [Abstract][Full Text] [Related]
6. Total inhibin is a potential serum marker for epithelial ovarian cancer.
Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibin and CA125 assays in the detection of ovarian cancer.
Robertson DM; Cahir N; Burger HG; Mamers P; McCloud PI; Pettersson K; McGuckin M
Clin Chem; 1999 May; 45(5):651-8. PubMed ID: 10222351
[TBL] [Abstract][Full Text] [Related]
8. Inhibins/activins as diagnostic markers for ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; Burger HG; McCloud P; Tsigos A; Groome N; Mamers P; McNeilage J; Jobling T; Healy D
Mol Cell Endocrinol; 2002 May; 191(1):97-103. PubMed ID: 12044923
[TBL] [Abstract][Full Text] [Related]
9. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
10. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
11. Inhibin forms in serum from postmenopausal women with ovarian cancers.
Robertson DM; Cahir N; Burger HG; Mamers P; Groome N
Clin Endocrinol (Oxf); 1999 Mar; 50(3):381-6. PubMed ID: 10435065
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-linked immunosorbent assay of total inhibin: direct determination based on inhibin alpha subunit-specific monoclonal antibodies.
Khosravi J; Krishna RG; Khaja N; Bodani U; Diamandi A
Clin Biochem; 2004 May; 37(5):370-6. PubMed ID: 15087252
[TBL] [Abstract][Full Text] [Related]
13. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
[TBL] [Abstract][Full Text] [Related]
14. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of inhibin in granulosa cell tumors of the ovary.
Jobling T; Mamers P; Healy DL; MacLachlan V; Burger HG; Quinn M; Rome R; Day AJ
Gynecol Oncol; 1994 Nov; 55(2):285-9. PubMed ID: 7959297
[TBL] [Abstract][Full Text] [Related]
17. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer.
Lambert-Messerlian GM; Steinhoff M; Zheng W; Canick JA; Gajewski WH; Seifer DB; Schneyer AL
Gynecol Oncol; 1997 Jun; 65(3):512-6. PubMed ID: 9190984
[TBL] [Abstract][Full Text] [Related]
18. [Inhibin and ovarian cancer].
Burger HG; Baillie A; Drummond AE; Healy DL; Jobling T; Mamers P; Robertson DM; Susil B; Cahir N; Shen Y; Verity K; Fuller PJ; Groome NP; Findlay JK
Vopr Onkol; 1999; 45(4):369-73. PubMed ID: 10532093
[TBL] [Abstract][Full Text] [Related]
19. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours.
Burger HG; Robertson DM; Cahir N; Mamers P; Healy DL; Jobling T; Groome N
Clin Endocrinol (Oxf); 1996 Apr; 44(4):413-8. PubMed ID: 8706307
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
